PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biopharmaceutical company focused on cell therapy for chronic kidney disease, trading publicly after completing its de-SPAC merger with SCS Capital Acquisition Corp., sponsored by SCS Capital Management, in 2022. The SPAC vehicle originally priced its IPO in 2021, targeting the healthcare and life sciences sector. ProKidney's lead investigational program, REACT, centers on renal autologous cell therapy aimed at slowing the progression of chronic kidney disease in adult patients. The company filed an 8-K current report with the SEC on May 15, 2026, accession number 0001193125-26-225848. For complete filing details, sponsor history, and real-time SPAC analytics on PROK and hundreds of other names, sign up for full data access at SpacDesk.